Welcome to the PROGEN Blog
Get the latest on AAV with our library of informative articles, new product announcements, customer stories and get to know the PROGEN team.
The Road To Even Safer AAV Gene Therapies
Although AAVs are among the safest gene therapy vectors, they do pose a few risks that can still be reduced.
Comparability Amid Change
When manufacturing changes bring challenges, standard reference materials can save the day.
Five Reasons to Choose Adeno-associated Viruses for Gene Therapy
These small but mighty DNA delivery vehicles are revolutionizing medicine.
Introducing Recombinant Adeno-associated Viruses (rAAV)
Modifying AAVs makes them more efficient and better at targeting specific tissues
Serving Customers’ Needs
Meet PROGEN’s Business Development Manager Jesse Kay and learn more about why it's important to solve customers problems.
Helping people become healthy
Meet PROGEN’s co-CEO Maik Lander and learn more about the importance of meeting customer´s needs.
Supporting the gene therapy community
Meet Katja Betts, co-CEO of PROGEN and find out why supporting the gene therapy community in developing new therapies is her everyday motivation.
